



## Meda acquires Women's Health products in the U.S.

- Meda acquires a portfolio of pharmaceutical products within Women's Health from Jazz Pharmaceuticals
- Meda increases the presence in an area where the company is active
- An experienced sales force of about 60 reps joins Meda
- Sales level around 200 MSEK and with good profitability
- Purchase price 95 MUSD, corresponding to 3 times sales

Meda has signed an agreement with the U.S. company Jazz Pharmaceuticals to acquire a portfolio of 6 pharmaceutical products focused on Women's Health. The largest and most important product is Elestrin, a patented product with sales of almost 100 MSEK. Elestrin is indicated for the treatment of moderate-to-severe vasomotor symptoms (i.e. hot flashes) associated with menopause. Since the launch in 2007, Elestrin has become a leading brand in the topical ERT (estrogen replacement therapy) market. Together with Meda's present portfolio of products in the therapy area of Women's Health the sales will be over 500 MSEK.

*"We can now strengthen the product offering in the U.S. as well as expand our sales force with people that have good experience and excellent track-record", said Anders Lönner, CEO of Meda AB. "Meda has already a presence in the Women's Health area and this deal will create positive marketing synergies".*

The closing of the acquisition is subject to the satisfaction of customary closing conditions and regulatory approvals, including antitrust approvals. With an anticipated closing of the acquisition during the 4<sup>th</sup> quarter this year, the effect on Meda's earnings per share is expected to be accretive already during 2013. Meda's existing credit facilities will finance the acquisition.

---

**For further inquiries, please contact:**

Anders Larnholt, Vice President Corporate Development & IR    ph: +46 709-458 878

---

**MEDA AB (publ)** is a leading international specialty pharma company. Meda's products are sold in 120 countries worldwide and the company is represented by its own organizations in 50 countries. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit [www.meda.se](http://www.meda.se).

**Forward-looking statements**

*This press release is not an offer to sell or a solicitation to buy shares in Meda. This press release also contains certain forward-looking statements with respect to certain future events and Meda's potential financial performance. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts, and may sometimes include words such as "may", "will", "seek", "anticipate", "expect", "estimate", "intend", "plan", "forecast", "believe" or other words of similar meaning. These forward looking statements reflect the current expectations on future events of the management at the time such statements are made, but are made subject to a number of risks and uncertainties. In the event such risks or uncertainties materialize, Meda's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with the inherent uncertainty of pharmaceutical research and product development, manufacturing and commercialization, the impact of competitive products, patents, legal challenges, government regulation and approval, Meda's ability to secure new products for commercialization and/or development and other risks and uncertainties detailed from time to time in Meda AB's interim or annual reports, prospectuses or press releases. Listeners and readers are cautioned that no forward-looking statement is a guarantee of future performance and that actual result could differ materially from those contained in the forward-looking statements. Meda does not intend, nor undertakes, to update any such forward looking statements.*